source
- Novo falls behind Eli Lilly in market race as investors react to Q3 resultsA year ago the competition between Eli Lilly and Novo was described as the fiercest in the industry. Recent commentary suggests the rivalry has become increasingly one‑sided, with Novo struggling t…
- Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stockSanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…